Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum κ and λ immunoglobulin free light chains (FLC): Inception of a new near-patient FLC screening tool

Clinical Chemistry and Laboratory Medicine

Volumn 55, Issue 3, 2017, Pages 424-434

  Campbell, John P ^a   Heaney, Jennifer L J ^a   Shemar, Meena ^b   Baldwin, Dene ^b   Griffin, Ann E ^a,b   Oldridge, Emma ^b   Goodall, Margaret ^a   Afzal, Zaheer ^a   Plant, Tim ^a   Cobbold, Mark ^a,c   Jefferis, Roy ^a   Jacobs, Joannes F M ^d   Hand, Christopher ^b   Drayson, Mark T ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Molecular Vision Ltd   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

free light chains; multiple myeloma; near patient testing

Indexed keywords

ANTIGEN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; POLYCLONAL ANTIBODY; IMMUNOGLOBULIN LIGHT CHAIN; TUMOR MARKER;

ARTICLE; CALIBRATION; COMPARATIVE STUDY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FREE LIGHT CHAIN ASSAY KIT; HUMAN; IMMUNOASSAY ANALYZER; IMMUNOGLOBULIN BLOOD LEVEL; LIMIT OF DETECTION; MULTIPLE MYELOMA; PORTABLE EQUIPMENT; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RETROSPECTIVE STUDY; SCREENING TEST; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; BLOOD; IMMUNOASSAY; PROCEDURES; REPRODUCIBILITY; STANDARD;

BIOMARKERS, TUMOR; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; LIMIT OF DETECTION; MULTIPLE MYELOMA; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS;

EID: 85012912741     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2016-0194     Document Type: Article

References (41)

1. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003;361:489-91.
2. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001;97:2900-2.
3. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78-84.
4. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ, 3rd, Colby CL, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010;375:1721-8.
5. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-44.
6. Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004;126:348-54.
7. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-80.
8. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-48.
9. Lyratzopoulos G, Neal RD, Barbiere JM, Rubin GP, Abel GA. Variation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 National Cancer Patient Experience Survey in England. Lancet Oncol 2012;13:353-65.
10. Elliss-Brookes L, McPhail S, Ives A, Greenslade M, Shelton J, Hiom S, et al. Routes to diagnosis for cancer-determining the patient journey using multiple routine data sets. Br J Cancer 2012;107:1220-6.
11. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005;23:9219-26.
12. Kariyawasan CC, Hughes DA, Jayatillake MM, Mehta AB. Multiple myeloma: causes and consequences of delay in diagnosis. Q J Med 2007;100:635-40.
13. Hutchison CA, Blade J, Cockwell P, Cook M, Drayson M, Fermand JP, et al. Novel approaches for reducing free light chains in patients with myeloma kidney. Nat Rev Nephrol 2012;8:234-43.
14. Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 2011;22:1129-36.
15. Hutchison CA, Batuman V, Behrens J, Bridoux F, Sirac C, Dispenzieri A, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 2012;8:43-51.
16. Friese CR, Abel GA, Magazu LS, Neville BA, Richardson LC, Earle CC. Diagnostic delay and complications for older adults with multiple myeloma. Leuk Lymphoma 2009;50:392-400.
17. Brioli A, Giles H, Pawlyn C, Campbell JP, Kaiser MF, Melchor L, et al. Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood 2014;123:3414-9.
18. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-24.
19. Tate J, Bazeley S, Sykes S, Mollee P. Quantitative serum free light chain assay-analytical issues. Clin Biochem Rev 2009;30:131-40.
20. Bradwell AR. Serum free light chain analysis (plus Hevylite), 6th ed. Birmingham: Binding Site Group, 2010.
21. Campbell JP, Cobbold M, Wang Y, Goodall M, Bonney SL, Chamba A, et al. Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine. J Immunol Methods 2013;391:1-13.
22. Nakano T, Nagata A. ELISAs for free light chains of human immunoglobulins using monoclonal antibodies: comparison of their specificity with available polyclonal antibodies. J Immunol Methods 2003;275:9-17.
23. Nakano T, Miyazaki S, Takahashi H, Matsumori A, Maruyama T, Komoda T, et al. Immunochemical quantification of free immunoglobulin light chains from an analytical perspective. Clin Chem Lab Med 2006;44:522-32.
24. Kim HS, Shin KS, Song W, Kim HJ, Park MJ. Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy. Biomed Res Int 2014;2014:647238.
25. Hoedemakers RM, Pruijt JF, Hol S, Teunissen E, Martens H, Stam P, et al. Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis. Clin Chem Lab Med 2012;50:489-95.
26. Schneider N, Wynckel A, Kolb B, Sablon E, Gillery P, Maquart FX. [Comparative analysis of immunoglobulin free light chains quantification by Freelite (The Binding Site) and N Latex FLC (Siemens) methods]. Ann Biol Clin (Paris) 2013;71:13-9. Etude comparative du dosage des chaines legeres libres d'immunoglobulines par technique Freelite (The Binding Site) et N Latex FLC (Siemens).
27. Pretorius CJ, Klingberg S, Tate J, Wilgen U, Ungerer JP. Evaluation of the N Latex FLC free light chain assay on the Siemens BN analyser: precision, agreement, linearity and variation between reagent lots. Ann Clin Biochem 2012;49:450-5.
28. Mollee P, Tate J, Pretorius CJ. Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis. Clin Chem Lab Med 2013;51:2303-10.
29. Lock RJ, Saleem R, Roberts EG, Wallage MJ, Pesce TJ, Rowbottom A, et al. A multicentre study comparing two methods for serum free light chain analysis. Ann Clin Biochem 2013;50:255-61.
30. Tate JR, Mollee P, Dimeski G, Carter AC, Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta 2007;376:30-6.
31. Jacobs JF, Hoedemakers RM, Teunissen E, van der Molen RG, te Velthuis H. Effect of sample dilution on two free light chain nephelometric assays. Clin Chim Acta 2012;413:1708-9.
32. Levinson SS. Hook effect with lambda free light chain in serum free light chain assay. Clin Chim Acta 2010;411:1834-6.
33. Daval S, Tridon A, Mazeron N, Ristori JM, Evrard B. Risk of antigen excess in serum free light chain measurements. Clin Chem 2007;53:1985-6.
34. Jacobs JF, van der Molen RG, Bossuyt X, Damoiseaux J. Antigen excess in modern immunoassays: to anticipate on the unexpected. Autoimmun Rev 2015;14:160-7.
35. Murata K, Clark RJ, Lockington KS, Tostrud LJ, Greipp PR, Katzmann JA. Sharply increased serum free light-chain concentrations after treatment for multiple myeloma. Clin Chem 2010;56:16-8.
36. Graziani MS, Merlini G. Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions. Expert Rev Mol Diagn 2014;14:55-66.
37. de Kat Angelino CM, Raymakers R, Teunesen MA, Jacobs JF, Klasen IS. Overestimation of serum kappa free light chain concentration by immunonephelometry. Clin Chem 2010;56:1188-90.
38. VanDuijn MM, Jacobs JF, Wevers RA, Engelke UF, Joosten I, Luider TM. Quantitative measurement of immunoglobulins and free light chains using mass spectrometry. Anal Chem 2015;87:8268-74.
39. Jacobs JF, Tate JR, Merlini G. Is accuracy of serum free light chain measurement achievable? Clin Chem Lab Med 2016;54:1021-30.
40. Graziani MS. Measurement of free light chains-pros and cons of current methods. Clin Chem Lab Med 2016;54:1015-20.
41. Drayson M, Carr-Smith H. Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis. Clin Chem Lab Med 2012;50:587-8.